Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of ...
Jun 8, 2013 | me-newswire.net
xml encoding="UTF-8"> ( BUSINESS WIRE )-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced several analyses of a phase III clinical trial of ABRAXANE® (paclitaxel protein-bound particles...
Read more...
ABRAXANE gemcitabine MPACT cancer pancreatic CA19-9 survival treatment metastatic patient